Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Gepubliceerd in:
hoofdstuk lezen eerste hoofdstuk lezen

2021 | OriginalPaper | Hoofdstuk

10. Schizofreniespectrum- en andere psychotische stoornissen

Auteurs : Arjen Peters, Drs. Liesanne Brakema, Drs. Marguerite van de Hoeve, Dr. Kor Spoelstra, Dr. Henderikus Knegtering

Gepubliceerd in: Slaapstoornissen in de psychiatrie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Slaap-waakstoornissen zijn voor mensen met psychosen, zoals schizofrenie en schizoaffectieve stoornissen, vaak een reden om hulp te zoeken. Het dag-nachtritme is bij mensen met psychosegevoeligheid vaak verstoord; mensen hebben meer moeite om in te slapen en/of door te slapen, en hebben vaker nachtmerries en slaapapneu. Er zijn sterke aanwijzingen dat afwijkingen in het slaappatroon een belangrijke rol spelen bij zowel de ontwikkeling als de verergering van psychosen. Slaaptekort of verminderde slaapkwaliteit kan namelijk ook bij gezonde personen psychoseachtige symptomen veroorzaken, met name hallucinaties en paranoïde wanen. Het blijft echter onduidelijk welke aspecten van de slaap betrokken zijn bij het ontstaan van een psychose dan wel of er gemeenschappelijke oorzaken bestaan voor het optreden van psychotische symptomen en slaapstoornissen. We geven een overzicht over de relatie tussen psychosen en verstoorde slaap en bespreken mogelijke onderliggende mechanismen en behandelopties.
vorige hoofdstuk Slaapgerelateerde bewegingsstoornissen
volgende hoofdstuk Stemmingsstoornissen
Literatuur
Addington, D. E., Patten, S. B., McKenzie, E., & Addington, J. (2013). Relationship between relapse and hospitalization in first-episode psychosis. Psychiatric Services, 64, 796–799.PubMedCrossRef
Aghajanian, G. K., & Marek, G. J. (2000). Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Research. Brain Research Reviews, 31(2–3), 302–312.PubMedCrossRef
Agosto, J., Choi, J. C., Parisky, K. M., Stilwell, G., Rosbash, M., & Griffith, L. C. (2008). Modulation of GABAA receptor desensitization uncouples sleep onset and maintenance in Drosophila. Nature Neuroscience, 11, 354–359.PubMedPubMedCentralCrossRef
American Psychiatric Association; Hengeveld, M. W. (2014). Handboek voor de classificatie van psychische stoornissen. Nederlandse vertaling van Diagnostic and statistical manual of mental disorders (5th ed.). Amsterdam: Boom.
Andersen, M. L., Martins, P. J., D’Almeida, V., Bignotto, M., & Tufik, S. (2005). Endocrinological and catecholaminergic alterations during sleep deprivation and recovery in male rats. Journal of Sleep Research, 14(1), 83–90.PubMedCrossRef
Anderson, K. N., & Bradley, A. J. (2013). Sleep disturbance in mental health problems and neurodegenerative disease. Nature and Science of Sleep, 5, 61–75.PubMedPubMedCentralCrossRef
Assimakopoulos, K., Karaivazoglou, K., Skokou, M., Kalogeropoulou, M., Kolios, P., Gourzis, P. et al. (2018). Genetic variations associated with sleep disorders in patients with schizophrenia: A systematic review. Medicines, 5(2). https://​doi.​org/​10.​3390/​medicines502002.
Baandrup, L., Glenthøy, B. J., & Jennum, P. J. (2016). Objective en subjective sleep quality: Melatonin versus placebo add-on treatment in patients with schizophrenia of bipolar disorder withdrawing from long-term benzodiazepine use. Psychiatry Research, 240, 163–169.PubMedCrossRef
Baran, B., Karahanoğlu, F., Mylonas, D., Demanuele, C., Vangel, M., Stickgold, R., et al. (2019). Increased thalamocortical connectivity in schizophrenia correlates with sleep spindle deficits: Evidence for a common pathophysiology. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 4, 706–714.
Bell, R. C., Farmer, S., Ries, R., & Srebnik, D. (2009). Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatric Services (Washington, D. C.), 60, 1686–1689.CrossRef
Benson, K. L. (2015). Sleep in schizophrenia: Pathology and treatment. Sleep Medicine Clinics, 10(1), 49–55.PubMedCrossRef
Bersani, G., Mameli, M., Garavini, A., Pancheri, P., & Nordio, M. (2003). Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuroendocrinology Letters, 24(3–4), 181–184.PubMed
Bleuler, E. (1950). In J. Zinkin & N. Lewis (Red.), Dementia praecox or the group of schizophrenias. New York: International Universities Press.
Bosch, P., Van Luijtelaar, G., Van den Noort, M., Lim, S., Egger, J., & Coenen, A. (2013). Sleep ameliorating effects of acupuncture in a psychiatric population (p. 969032). Altern Med: Evid Based Complement.
Bosch, P., Staudte, H., Van den Noort, M., & Lim, S. (2014). A case study on acupuncture in the treatment of schizophrenia. Acupuncture in Medicine, 32, 286–289.PubMedCrossRef
Bosch, P., Lim, S., Yeo, S., Lee, S. H., Staudte, H., & Van den Noort, M. (2016a). Acupuncture in the treatment of a female patient suffering from chronic schizophrenia and sleep disorders. Case Reports Psychiatry, 2016, 6745618.CrossRef
Bosch, P., Van den Noort, M., Staudte, H., Lim, S., Yeo, S., Coenen, A., et al. (2016b). Sleep disorders in patients with depression or schizophrenia: A randomized controlled trial using acupuncture treatment. European Journal of Integrative Medicine, 8, 789–796.CrossRef
Bosch, P., Staudte, H., Yeo, S., Lee, S. H., Lim, S., & Van den Noort, M. (2017). Acupuncture treatment of a male patient suffering from long-term schizophrenia and sleep disorders. Journal of Traditional Chinese Medicine, 37, 862–867.CrossRef
Bosch, P., Lim, S., Staudte, H., Yeo, S., Lee, S. H., Barisch, P., et al. (2018). Pharmacological treatment for long-term patients with schizophrenia and its effects on sleep in daily clinical practice: A pilot study. Medicines, 5, 44.PubMedCentralCrossRef
Boufidis, S., Kosmidis, M. H., & Bozikas, V. P. (2003). Treatment outcome of obstructive sleep apnea syndrome in a patient with schizophrenia: Case report. International Journal of Psychiatry in Medicine, 33(3), 305–310.PubMedCrossRef
Brabban, A., Morrison, T., & Read, J. (2013). Renaming ‘schizophrenia’: A step too far or not far enough? Psychological Medicine, 43, 1558–1560.PubMedCrossRef
Brannen, J. O., & Jewett, R. E. (1969). Effects of selected phenothiazines on REM sleep in schizophrenics. Archives of General Psychiatry, 21(3), 284–290.PubMedCrossRef
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., et al. (2005). The efficacy and safety of exogenous melatonin for primary sleep disorders: A meta-analysis. Journal of General Internal Medicine, 20, 1151–1158.PubMedPubMedCentralCrossRef
Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L., et al. (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ, 332, 385–393.PubMedPubMedCentralCrossRef
Büschlen, J., Berger, G. E., Borgwardt, S. J., Aston, J., Gschwandtner, U., Pfluegree, M. O., et al. (2011). Pituitary volume increase during emerging psychosis. Schizophrenia Research, 125(1), 41–48.PubMedCrossRef
Canellas, F., Lin, L., Julià, M. R., Clemente, A., Vives-Bauza, C., Ollila, H. M., et al. (2014). Dual cases of type 1 narcolepsy with schizophrenia and other psychotic disorders. Journal of Clinical Sleep Medicine, 10, 1011–1018.PubMedPubMedCentralCrossRef
Chan, Y. Y., Lo, W. Y., Yang, S. N., Chen, Y. H., & Lin, J. G. (2015). The benefit of combined acupuncture and antidepressant medication for depression: A systematic review and meta-analysis. Journal of Affective Disorders, 176, 106–117.PubMedCrossRef
Chemerinski, E., Ho, B., Flaum, M., Arndt, S., Fleming, F., & Andreasen, N. C. (2002). Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Sleep Medicine Reviews, 31, 25–38.
Chouinard, S., Poulin, J., Stip, E., & Godbout, R. (2004). Sleep in untreated patients with schizophrenia: A meta-analysis. Schizophrenia Bulletin, 30(4), 957–967.PubMedCrossRef
Cohrs, S., Rodenbeck, A., & Guan, Z. (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacol, 174(3), 421–429.CrossRef
Cohrs, S., Meier, A., Neumann, A. C., Jordan, W., Rüther, E., & Rodenbeck, A. (2005). Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: A randomized, controlled, crossover trial of 12 healthy male subjects. Journal of Clinical Psychiatry, 66(8), 989–996.CrossRef
Coodin, S. (2001). Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry, 46, 549–555.PubMedCrossRef
Dauvilliers, Y., Arnulf, I., & Mignot, E. (2007). Narcolepsy with cataplexy. Lancet, 369, 499–511.PubMedCrossRef
Davies, G., Haddock, G., Yung, A. R., Mulligan, L. D., & Kyle, S. D. (2017). A systematic review of the nature and correlates of sleep disturbance in early psychosis. Sleep Medicine Reviews, 31, 25–38.PubMedCrossRef
De Filippis, D., Iuvone, T., Esposito, G., Steardo, L., Arnold, G. H., Paul, A. P., et al. (2008). Melatonine reverses lipopolysaccharide-induced gastro-intestinal motility distrurbances through the inhibition of oxidative stress. Journal of Pineal Research, 44, 45–51.PubMed
Doknic, M., Pekic, S., Zarkovic, M., Medic-Stojanoska, M., Dieguez, C., Casanueva, F., et al. (2002). Dopaminergic tone and obesity: An insight from prolactinomas treated with bromocriptine. European Journal of Endocrinology, 147(1), 77–84.PubMedCrossRef
Edinger, J., Wohlgemuth, W., Radtke, R., Marsh, G., & Quillian, R. (2001). Cognitive behavioral therapy for treatment of chronic primary insomnia. JAMA, 285, 1856–1864.PubMedCrossRef
Espie, C. A. (2006). Overcoming Insomnia and Sleep Problems: A self help guide using cognitive behavioural techniques. London: Constable and Robinson.
Espino, J., Pariente, J. A., & Rodríguez, A. B. (2011). Role of melatonin on diabetes-related metabolic disorders. World Journal of Diabetes, 2, 82–91.PubMedPubMedCentralCrossRef
Fang, F., Sun, H., Wang, Z., Ren, M., Calabrese, J. R., & Gao, K. (2016a). Antipsychotic drug-induced somnolence: Incidence, mechanisms, and management. CNS Drugs, 30, 845–867.PubMedCrossRef
Fang, S. H., Suzuki, K., Lim, C. L., et al. (2016b). Associations between sleep quality and inflammatory markers in patients with schizophrenia. Psychiatry Research, 246, 154–160.PubMedCrossRef
Farde, L. (1992). Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans: A PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology (Berl), 107, 23–29.CrossRef
Faulkner, S. M., Bee, P. E., Meyer, N., Dijk, D.-J., & Drake, R. J. (2019). Light therapies to improve sleep in intrinsic circadian rhythm sleep disorder and neuro-psychiatric illness: A systematic review and meta-analysis. Sleep Medicine Reviews, 46, 108–123.PubMedCrossRef
Ferrarelli, F., Peterson, M. J., Sarasso, S., Riedner, B. A., Murphy, M. J., Benca, R. M., et al. (2010). Thalamic dysfunction in schizophrenia suggested by whole-night deficits in slow and fast spindles. American Journal of Psychiatry, 167(11), 1339–1348.CrossRef
Freeman, D., Pugh, K., Vorontsova, N., & Southgate, L. (2009). Insomnia and paranoia. Schizophrenia Research, 108, 280–284.PubMedCrossRef
Freeman, D., Waite, F., Startup, H., Myers, E., Lister, R., McInerney, J., et al. (2015). Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): A prospective, assessor-blind, randomised controlled pilot trial. Lancet Psychiatry, 2, 975–983.PubMedPubMedCentralCrossRef
Freeman, D., Sheaves, B., Goodwin, G. M., Yu, L.-M., Nickless, A., Harrison, P. J., et al. (2017). The effects of improving sleep on mental health (OASIS): A randomised controlled trial with mediation analysis. Lancet Psychiatry, 4, 749–758.PubMedPubMedCentralCrossRef
Garner, B., Pariante, C. M., Wood, S. J., Velakoulis, D., Phillips, L., Soulsby, B., et al. (2005). Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry, 58, 417–423.PubMedCrossRef
Gillin, J. C., Van Kammen, D. P., Post, R., & Bunney, W. E. (1977). Effects of prolonged administration of pimozide on sleep-EEG patterns in psychiatric patients. Communications in Psychopharmacology, 1(3), 225–232.PubMed
Gimenez, S., Clos, S., Romero, S., Grasa, E., Morte, A., & Barbanoj, M. J. (2007). Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacology (Berl), 190(4), 507–516.CrossRef
Greenman, Y., Tordjman, K., & Stern, N. (1998). Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels. Clinical Endocrinology, 48(5), 547–553.PubMedCrossRef
Gupta, M. A., & Simpson, F. C. (2015). Obstructive sleep apnea and psychiatric disorders: A systematic review. Journal of Clinical Sleep Medicine, 11, 165–175.PubMedPubMedCentralCrossRef
Hartz, S. M., Pato, C. N., Medeiros, H., Cavazos-Rehg, P., Sobell, J. L., Knowles, J. A., et al. (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry, 71(3), 248.PubMedPubMedCentralCrossRef
Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and Therapy, 40, 869–893.CrossRefPubMed
Hermes, E. D. A., Sernyak, M., & Rosenhecck, R. (2013). Use of second-generation antipsychotic agents for sleep and sedation: A provider survey. Sleep, 36, 597–600.PubMedPubMedCentralCrossRef
Hinze-Selch, D., Mullington, J., Orth, A., Lauer, C. J., & Pollmacher, T. (1997). Effects of clozapine on sleep: A longitudinal study. Biological Psychiatry, 42(4), 260–266.PubMedCrossRef
Hornyak, M., Feige, B., Riemann, D., & Voderholzer, U. (2006). Periodic leg movements in sleep and periodic limb movement disorder: Prevalence, clinical significance and treatment. Sleep Medicine Reviews, 10, 169–177.PubMedCrossRef
Huang, Y., & Zheng, Y. (2015). Sleep disorder of schizophrenia treated with shallow needling: A randomized controlled trial. Zhongguo Zhen Jiu, 35, 869–873.PubMed
Huang, Y. S., Guilleminault, C., Chen, C. H., Lai, P. C., & Hwang, F. M. (2014). Narcolepsy-cataplexy and schizophrenia in adolescents. Sleep Medicine, 15, 15–22.PubMedCrossRef
Hung, C. C., Liao, C. C., Wu, P. L., Lee, S. D., & Lane, H. Y. (2014). Metabolic abnormality and sleep disturbance are associated with clinical severity of patients with schizophrenia. BioMedicine, 4(1), 6.
Igwe, S. C., & Brigo, F. (2018). Does melatonin and melatonin agonists improve the metabolic side effects of atypical antipsychotics? A systematic review and meta-analysis of randomized controlled trials. Clinical Psychopharmacology and Neuroscience, 16, 235–245.PubMedPubMedCentralCrossRef
Irwin, M. R., Olmstead, R., & Carroll, J. E. (2016). Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biological Psychiatry, 80, 40–52.PubMedCrossRef
Irwin, M. R., Olmstead, R., Breen, E. C., Witarama, T., Carrillo, C., Sadeghi, N., et al. (2015). Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: A randomized controlled trial. Biological Psychiatry, 78, 721–729.PubMedPubMedCentralCrossRef
Isaac, S. O., & Berridge, C. W. (2003). Wake-promoting actions of dopamine D1 and D2 receptor stimulation. Journal of Pharmacology and Experimental Therapeutics, 307(1), 386–394.CrossRef
Jiang, H. K., & Wang, J. Y. (1998). Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. Journal of the Formosan Medical Association, 97(12), 830–837.PubMed
Johansson, A. F., Owe-Larsson, B., Hetta, J., & Lundkvist, G. B.(2016). Altered circadian clock gene expression in patients with schizophrenia. Schizophrenia Research, 174(1–3), 17–23.
Ka-Fai, C., Yuan-Ping, P. Y. P., Ting-Kin, N., & Chui-Kwan, K. (2018). Correlates of sleep irregularity in schizophrenia. Psychiatry Research, 270, 705–714.CrossRef
Kajimura, N., Kato, M., Okuma, T., Masanori, S., Tsuyoshi, W., & Kiyohisa, T. (1995). A quantitative sleep-EEG study on the effects of benzodiazepine and zopiclone in schizophrenic patients. Schizophrenia Research, 15, 303–312.PubMedCrossRef
Kalucy, M. J., Grunstein, R., Lambert, T., & Glozier, N. (2013). Obstructive sleep apnoea and schizophrenia – A research agenda. Sleep Medicine Reviews, 17(5), 357–365.PubMedCrossRef
Kamath, J., Virdi, S., & Winokur, A. (2015). Sleep disturbances in schizophrenia. Psychiatric Clinics of North America, 38(4), 777–792.CrossRef
Kanno, O., Watanabe, H., & Kazamatsuri, H. (1993). Effects of zopiclone, flunitrazepam, triazolam and levomepromazine on the transient change in sleep-wake schedule: Polygraphic study, and the evaluation of sleep and daytime condition. Progress in Neuropsychopharmacology and Biological Psychiatry, 17(2), 229–239.CrossRef
Kantrowitz, J., Citrome, L., & Javitt, D. (2009). GABAB receptors, schizophrenia and sleep dysfunction: A review of the relationship and its potential clinical and therapeutic implications. CNS Drugs, 23, 681–691.PubMedPubMedCentralCrossRef
Karanti, A., & Landén, M. (2007). Treatment refractory psychosis remitted upon treatment with continuous positive airway pressure: A case report. Psychopharmacology Bulletin, 40, 113–117.PubMed
Kaskie, R. E., Gill, K. M., & Ferrarelli, F. (2018). Reduced frontal slow wave density during sleep in first-episode psychosis. Schizofrenia Research, 206, 318–324.CrossRef
Kaskie, R. E., & Ferrarelli, F. (2019). Sleep disturbances in schizophrenia: What we know, what still needs to be done. Current Opinion in Psychology, 34, 68–71.PubMedCrossRefPubMedCentral
Kesler, R. C., Amminger, G. P., Aguilar-Gaxiola, S., Alonso, J., Lee, S., & Ustun, T. B. (2007). Age of onset of mental disorders: A review of recent literature. Current Opinion in Psychiatry, 20, 359–364.CrossRef
Kishi, Y., Konishi, S., Koizumi, S., Kudo, Y., Kurosawa, H., & Kathol, R. G. (2004). Schizophrenia and narcolepsy: A review with a case report. Psychiatry and Clinical Neurosciences, 58, 117–124.PubMedCrossRef
Kraepelin, E. (1919). In R. Barclay & G. Robertson (rred.), Dementia praecox and paraphrenia. Chicago: Chicago Medical Book Co.
Krystal, A. D., & Zammit, G. (2016). The sleep effects of lurasidone: A placebo-controlled cross-over study using a 4-h phase-advance model of transient insomnia. Human Psychopharmacology Clinical and Experimental, 31, 206–216.PubMedCrossRef
Krystal, A. D., Goforth, H. W., & Roth, T. (2008). Effects of antipsychotic medications on sleep in schizophrenia. International Clinical Psychopharmacology, 23, 150–160.PubMedCrossRef
Kumar, S. P. N., Andrade, C., Bhakta, S. G., & Singh, N. M. (2007). Melatonin in schizophrenic outpatients with insomnia: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 68, 237–241.CrossRef
Kyoung-Sae, N., Han-Yong, J., & Yong-Ku, K. (2014). The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 48, 277–286.CrossRef
Laskemoen, J. F., Simonsen, C., Büchmann, C., Barrett, E. A., Bjella, T., Lagerberg, T. V., et al. (2019). Sleep disturbances in schizophrenia spectrum and bipolar disorders – A transdiagnostic perspective. Comprehensive Psychiatry, 91, 6–12.PubMedCrossRef
Lee, J. H., Woo, J. I., & Meltzer, H. Y. (2001). Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatry Research, 103(2–3), 157–166.PubMedCrossRef
Lee, E. E., Ancoli-Israel, S., Eyler, L. T., Tu, X. M., Palmer, B., Irwin, M. R., et al. (2019). Sleep disturbances and inflammatory biomarkers in schizophrenia: Focus on sex differences. The American Journal of Geriatric Psychiatry, 27(1), 21–31.PubMedCrossRef
Li, S. X., Lam, S. P., Zhang, J., Yu, M., Chan, J., Chan, C., et al. (2016). Sleep disturbances and suicide risk in an 8-year longitudinal study of schizophrenia-spectrum disorders. Sleep, 39, 1275–1282.PubMedPubMedCentralCrossRef
Li, M., Wang, R., Zhao, M., Zhai, J., Liu, B., Yu, D., et al. (2019). Abnormalities of thalamus volume and resting state functional connectivity in primary insomnia patients. Brain Imaging Behavior, 13, 1193–1201.PubMedCrossRef
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, M. A., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209–1223.CrossRef
Lunsford-Avery, J. R., LeBourgeois, M. K., Gupta, T., & Mittal, V. A. (2015). Actigraphic-measured sleep disturbance predicts increased positive symptoms in adolescents at ultra high-risk for psychosis: A longitudinal study. Schizophrenia Research, 164, 15–20.PubMedCrossRef
Luthringer, R., Staner, L., Noel, N., Muzet, M., Gasmann-Mayer, C., Talluri, K., et al. (2007). A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. International Clinical Psychopharmacology, 22(5), 299–308.PubMedCrossRef
Maixner, S., Tandon, R., Eiser, A., Taylor, S., DeQuardo, J. R., & Shipley, J. (1998). Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: A replication and extension. American Journal of Psychiatry, 155(11), 1600–1602.CrossRef
Maldonado, M. D., Pérez-San-Gregorio, M. A., & Reiter, R. J. (2009a). The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Patents on CNS Drug Discovery, 4(1), 61–69.PubMedCrossRef
Maldonado, M. D., Reiter, R. J., & Pérez-San-Gregorio, M. A. (2009b). Melatonin as a potential therapeutic agent in psychiatric illness. Human Psychopharmacology, 24(5), 391–400.PubMedCrossRef
Mansour, H. A., Wood, J., Logue, T., Chowdari, K. V., Dayal, M., Kupfer, D. J., et al. (2006). Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes, Brain and Behavior, 5(2), 150–157.CrossRef
McClave, A., McKnight-Eily Davis, S., & Dube, S. (2007). Smoking characteristics of adults with selected lifetime mental illnesses: Results from the 2007 national health interview survey. American Journal of Public Health, 100, 2464–2472.CrossRef
McMillan, K. B., Enns, M. M. F., Cox, B. P., & Sareen, J. M. F.(2009). Comorbidity of axis I and II mental disorders with schizophrenia and psychotic disorders: Findings from the National epidemiologic survey on alcohol and related conditions. The Canadian Journal of Psychiatry, 54, 477.
Meng, Q., Li, R., Hou, F., & Zhang, Q. (2018). Effects of chloorpromazine on sleep quality, clinical and emotional measures among patients with schizohrenia. Clinical Neurology and Neurosurgery, 165, 134–138.PubMedCrossRef
Meyer, J. M., & Stahl, S. M. (2009). The metabolic syndrome and schizophrenia. Acta Psychiatrica Scandinavica, 119, 4–14.PubMedCrossRef
Meyer, U., Feldon, J., & Dammann, O. (2011). Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatric Research, 69(5 Pt 2), 26R–33R.PubMedPubMedCentralCrossRef
Mignot, E., Lammers, G. J., Ripley, B., Okun, M., Nevsimalova, S., Overeem, S., et al. (2001). The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of Neurology, 59, 1553–1562.CrossRef
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry, 70, 663–671.PubMedPubMedCentralCrossRef
Mondelli, V., Dazzan, P., Hepgul, N., Di, F. M., Aas, M., D’Albenzio, A., et al. (2010). Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophrenia Research, 116, 234–242.PubMedCrossRef
Monteleone, P., Maj, M., Fusco, M., Kemali, D., & Reiter, R. J. (1992). Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophrenia Research, 7(1), 77–84.PubMedCrossRef
Monti, J. M. (2011). Serotonin control of sleep-wake behavior. Sleep Medicine Reviews, 15, 269–281.PubMedCrossRef
Monti, J. M., Bahamman, A. S., Pandi-Perumal, S. R., Bromundt, V., Spence, D. W., Cardinal, D. P., et al. (2013). Sleep and circadian rhythm dysregulation in schizofrenia. Progress in Neuropsychopharmacology and Biological Psychiatry, 43, 209–216.CrossRef
Monti, J. M., Torterolo, P., Seithikurippu, R., & Perumal, P. (2018). The effects of second generation antipsychotic drugs on sleep variables in healthy subjects in patients with schizophrenia. Sleep Medicine Reviews, 33, 51–57.CrossRef
Morgan, P. T., Pace-Schott, E. F., Mason, G. F., Forselius, E., Fasula, M., Valentine, G. W., et al. (2012). Cortical GABA levels in primary insomnia. Sleep, 35, 807–814.PubMedPubMedCentralCrossRef
Motivala, S. J. (2011). Sleep and inflammation: Psychoneuroimmunology in the context of cardiovascular disease. Motivala SJ. Annals of Behavioral Medicine, 42(2), 141–152.PubMedCrossRef
Müller, M. J., Rossbach, W., Mann, K., Röschke, J., Müller-Siecheneder, J., Blümler, M., et al. (2004). Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms. Pharmacopsychiatry, 37(4), 157–162.PubMedCrossRef
Murai, T., Nakamichi, K., Shimizu, I., & Ikeda, K. (2014). Lurasidone suppresses rapid eye movement sleep and improves sleep quality in rats. Journal of Pharmacological Sciences, 126, 164–167.PubMedCrossRef
Muthukumaraswamy, S. D., Edden, R. A., Jones, D. K., Swettenham, J. B., & Singh, K. D. (2009). Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proceedings of National Academy of Sciences, 106, 8356–8361.CrossRef
Myles, H., Myles, N., Antic, N. A., Adams, R., Chandratilleke, M., Liu, D., et al. (2016). Obstructive sleep apnea and schizophrenia: A systematic review to inform clinical practice. Schizophrenia Research, 170(1), 222–225.PubMedCrossRef
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A., Spiliotacopoulos, D., Bruxner, A., et al. (2013). Long-term follow-up of a group at ultra high risk (“Prodromal”) for psychosis: The PACE 400 study. JAMA Psychiatry, 70(8), 793–802.PubMedCrossRef
Neylan, T. C., Van Kammen, D. P., Kelley, M. E., & Peters, J. L. (1992). Sleep in schizophrenic patients on and off haloperidol therapy: Clinically stable vs relapsed patients. Archives of General Psychiatry, 49(8), 643–649.PubMedCrossRef
Nofzinger, E. A., Van Kammen, D. P., Gilbertson, M. W., Gurklis, J. A., & Peters, J. L. (1993). Electroencephalographic sleep in clinically stable schizophrenic patients: Two-weeks versus six-weeks neuroleptic-free. Biological Psychiatry, 33(11–12), 829–835.PubMedCrossRef
Ohayon, M. M. (2002). Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews, 6(2), 97–111.PubMedCrossRef
Pakes, G., Brogden, R., Heel, R., Speight, T. M., & Avery, T. S. (1981). Triazolam: A review of its pharmacological properties and therapeutic efficacy in patients with insomnia. Drugs, 22(2), 81–110.PubMedCrossRef
Park, H. J., Park, J. K., Kim, S. K., Cho, A. R., Kim, J. W., Yim, S. V., et al. (2011). Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. Journal of Molecular Neuroscience, 45(2), 304–308.PubMedCrossRef
Partinen, M., & Telakivi, T. (1992). Epidemiology of obstructive sleep apnea syndrome. Sleep, 15(6), 1–4.CrossRef
Patatanian, E., & Claborn, M. K. (2018). Drug-induced restless legs syndrome. Annals of Pharmacotherapy, 52, 662–672.CrossRef
Patel, N., LeWitt, P., Neikrug, A. B., Kesslak, P., Coate, B., & Ancoli-Israel, S. (2018). Nighttime sleep and daytime sleepiness improved with pimavanserin during treatment of Parkinson’s disease psychosis. Clinical Neuropharmacology, 41(6), 210–215.PubMedCrossRef
Plante, D. T., Jensen, J. E., Schoerning, L., & Winkelman, J. W. (2012). Reduced gamma-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: A link to major depressive disorder? Neuropsychopharmacology, 37, 1548–1557.PubMedPubMedCentralCrossRef
Porfirio, M.-C., Gomes de Almeida, J. P., Stornelli, M., Giovinazzo, S., Purper-Ouakil, D., & Masi, G. (2017). Can melatonin prevent or improve metabolic side effects during antipsychotic treatments? Neuropsychiatric Disease and Treatment, 13, 2167–2174.PubMedPubMedCentralCrossRef
Porjesz, B., Almasy, L., Edenberg, H. J., Wang, K., Chorlian, D. B., Foroud, T., et al. (2002). Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus. Proceedings of National Academy of Sciences, 99, 3729–3733.CrossRef
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biological Psychiatry, 63, 801–808.PubMedCrossRef
Pritchett, D., Wulff, K., Oliver, P. L., Bannerman, D. M., Davies, K. E., Harrison, P. J., et al. (2012). Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. Journal of Neural Transmission, 119, 1061–1075.PubMedCrossRef
Raskind, M. A., Burke, B. L., Crites, N. J., Tapp, A. M., & Rasmussen, D. D. (2007). Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology, 32, 284–288.PubMedCrossRef
Reeve, S., Sheaves, B., & Freeman, D. (2015). The role of sleep disfunction in the occurrence of delusions and hallucinations: A systematic review. Clinical Psychology Review, 42, 96–115.PubMedPubMedCentralCrossRef
Reeve, S., Sheaves, B., & Freeman, D. (2018). Sleep disorders in early psychosis: Incidence, severity and association with clinical symptoms. Schizophrenia Bulletin, 45(2), 287–295.PubMedCentralCrossRef
Reshev, A., Bloch, B., Vadas, L., Ravid, S., Kremer, I., & Haimov, I. (2013). The effects of acupuncture treatment on sleep quality and on emotional measures among individuals living with schizophrenia: A pilot study. Sleep Disorder, 2013, 327820.
Riemann, D., Spiegelhalder, K., Feige, B., et al. (2010). The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Medicine Reviews, 14(1), 19–31.PubMedCrossRef
Ripke, S., Sanders, A. R., Kendler, K. S., Levinson, D. F., Sklar, P., Holmans, P. A., et al. (2011). Genome-wide association study identifies five new schizophrenia loci. Nature Genetics, 2011(43), 969–976.
Rishi, M. A., Shetty, M., Wol, A., Amoateng-Adjepong, Y., & Manthous, C. A. (2010). Atypical antipsychotic medications are independently associated with severe obstructive sleep apnea. Clinical Neuropharmacology, 33, 109–113.PubMedCrossRef
Rodriguez, C., Mayo, J. C., Sainz, R. M., Antolín, I., Herrera, F., Martín, V., et al. (2004). Regulation of antioxidant enzymes: A significant role for melatonin. Journal of Pineal Research, 36, 1–9.PubMedCrossRef
Rowland, L. M., & Wickwire, E. M. (2019). A wake-up Call: Assess and treat sleep disorders in early psychosis. Schizophrenia Bulletin, 45(2), 265–266.PubMedCrossRef
Rüther, E., Davis, L., Papousek, M., Reichinger, M., Reiter, H., & Rudolph, M. (1976). Pharmakologische beeinflussung zentraler serotonerger mechanismen am menschen und auswirkungen auf den schlaf. Arzneimittel-Forschung, 26(6), 1071–1073.PubMed
Ryan, M. C., Sharifi, N., Condren, R., & Thakore, J. H. (2004). Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology, 29, 1065–1070.PubMedCrossRef
Sahbaz, C., Özer, O. F., Kurtulmus, A., Kirpinar, I., Sahin, F., & Guloksuz, S. (2019). Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. Metabolic Brain Disease, 34(3), 865–874.PubMedCrossRef
Saletu, B., Anderer, P., Brandstätter, N., Frey, R., Grünberger, J., Klösch, G., et al. (1994). Insomnia in generalized anxiety disorder: Polysomnographic, psychometric and clinical investigations before, during and after therapy with a long-versus a short-half-life benzodiazepine (quazepam versus triazolam). Neuropsychobiology, 29(2), 69–90.PubMedCrossRef
Salin-Pascual, R. J., Herrera-Estrella, M., Galicia-Plo, L., Rosas, M., & Brunner, E. (2004). Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients. Revista de Investigacion Clinica, 56(3), 345–350.PubMed
Salin-Pascual, R. J., Herrera-Etrella, M., Galicia-Polo, L., & Laurrabaguio, M. R. (1999). Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biological Psychiatry, 46(1), 141–143.PubMedCrossRef
Sansa, G., Gavaldà, A., Gaig, C., Monreal, J., Ercilla, G., Casamitjana, R., et al. (2016). Exploring the presence of narcolepsy in patients with schizophrenia. BMC Psychiatry, 16, 177.PubMedPubMedCentralCrossRef
Saper, C. B., Chou, T. C., & Scammell, T. E. (2001). The sleep switch: Hypothalamic control of sleep and wakefulness. Trends in Neurosciences, 24, 726–731.PubMedCrossRef
Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., et al. (1996). Risperidone compared with new and reference antipsychotics drugs: In vitro and in vivo receptor binding. Psychopharmacology, 124, 57–73.PubMedCrossRef
Sekine, Y., Rikihisa, T., Ogata, H., Echizen, H., & Arakawa, Y. (1999). Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. European Journal of Clinical Pharmacology, 55, 583–587.PubMedCrossRef
Shamir, E., Laudon, M., Barak, Y., Anis, Y., Rotenberg, V., Elizur, A., et al. (2000). Melatonin improves sleep quality of patients with chronic schizophrenia. The Journal of Clinical Psychiatry, 61, 373–377.
Sheaves, B., Bebbington, P., Goodwin, G., Harrison, P. J., Espie, C. A., Foster, R. G., et al. (2016). Insomnia and hallucinations in the general population: Findings from the 2000 and 2007 British psychiatric morbidity surveys. Psychiatry Research, 241(7), 141–146.PubMedPubMedCentralCrossRef
Sheaves, B., Freeman, D., Isham, L., McInerey, J., Nickless, A., Yu, L. M., et al. (2018). Stabilising sleep for patients admitted at acute crisis to a psychiatric hospital (OWLS): An assessor-blind pilot randomised controlled trial. Psychological Medicine, 48, 1694–1704.PubMedCrossRef
Sheaves, B., Onwumere, J., Keen, N., Stahl, D., & Kuipers, E. (2015). Nightmares in patients with psychosis: The relation with sleep, psychotic, affective, and cognitive symptoms. Canadian Journal of Psychiatry, 60, 354–361.PubMedCrossRefPubMedCentral
Stummer, L., Markovic, M., & Maroney, M. (2018). Pharmacologic treatment options for insomnia in patients with schizophrenia. Medicines, 5, 88.PubMedCentralCrossRef
Takahashi, T., Nakamura, K., Nishiyama, S., Furuichi, A., Ikeda, E., Kido, M., et al. (2013). Increased pituitary volume in subjects at risk for psychosis and patients with first-episode schizophrenia. Psychiatry and Clinical Neurosciences, 67(7), 540–548.PubMedCrossRef
Takao, T., Tachikawa, H., Kawanishi, Y., Mizukami, K., & Asada, T. (2007). Clock gene T3111C polymorphism is associated with Japanese schizophrenics: A preliminary study. European Neuropsychopharmacology, 17(4), 273–276.PubMedCrossRef
Tandon, R. (1997). Effects of atypical antipsychotics on polysomnographic measures in schizophrenia. In L. L. Judd, B. Saletu, & V. Filip (rred.), Basic and clinical science of mental and addictive disorders (Bd. 167, pag. 219–222). Basel: Karger.CrossRef
Taylor, M. J., Gregory, A. M., & Freeman, D. (2015). Do sleep disturbances and psychotic-like experiences in adolescence share genetic and environmental influences? Journal of Abnormal Psychology, 124(3), 674–684.PubMedPubMedCentralCrossRef
Tek, C., Palmese, L. B., Krystal, A. D., Srihari, V. H., DeGeorge, P., Reutenaur, E. L., et al. (2014). The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: A double-blind, randomized, placebo-controlled trial. Schizophrenia Research, 160, 180–185.PubMedCrossRef
Thaker, G. K., Wagman, A. M., Kirkpatrick, B., & Tamminga, C. A. (1989). Alterations in sleep polygraphy after neuroleptic withdrawal: A putative supersensitive dopaminergic mechanism. Biological Psychiatry, 25(1), 75–86.PubMedCrossRef
Thakore, J. H., Mann, J. N., Vlahos, H., Martin, A., & Reznek, R. (2002). Increased visceral fat distribution in drug-naive and drug -free patients with schizophrenia. International Journal of Obesity and Related Metabolic Disorders, 26, 137–141.PubMedCrossRef
Touyz, S. W., Beumont, P. J., Saayman, G. S., & Zabow, T. (1977). A psychophysiological investigation of the short-term effects of clozapine upon sleep parameters of normal young adults. Biological Psychiatry, 12(6), 801–822.PubMed
Touyz, S. W., Saayman, G. S., & Zabow, T. A. (1978). A psychophysiological investigation of the long-term effects of clozapine upon sleep patterns of normal young adults. Psychopharmacology (Berl), 56(1), 69–73.CrossRef
Van Alphen, A., Ammeraal, M., Blanke, C., Boonstra, N., Boumans, H., Bruggeman, R., et al. (2012). Multidisciplinaire richtlijn schizofrenie. Utrecht: De Tijdstroom.
Van den Noort, M., Yeo, S., Lim, S., Lee, S. H., Staudte, H., & Bosch, P. (2018). Acupuncture as add-on treatment of the positive, negative, and cognitive symptoms of patients with schizophrenia: A systematic review. Medicines, 5, 29.PubMedCentralCrossRef
Varese, F., Smeets, F., Drukker, M., Lieverse, R., Lataster, T., Viechtbauer, W., et al. (2012). Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prosepctive- and cross-sectional cohort studies. Schizophrenia Bulletin, 38, 661–671.PubMedPubMedCentralCrossRef
Vigano, D., Lissoni, P., Rovelli, F., Roselli, M. G., Malugani, F., Gavazzeni, C., et al. (2001). A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuroendocrinology Letters, 22(2), 137–141.PubMed
Waddington Lamont, E. W., Coutu, D. L., Cermakian, N., & Boivin, D. B. (2010). Circadian rhythms and clock genes in psychotic disorders. The Isreal Journal of Psychiatry and Related Sciences, 47(1), 27–35.
Waite, F., Evans, N., Myers, E., Startup, H., Lister, R., Harvey, A. G., et al. (2015). The patient experience of sleep problems and their treatment in the context of current delusions and hallucinations. Psychology and Psychotherapy: Theory, Research and Practice, 89(2), 181–193.CrossRef
Waite, F., Myers, E., Harvey, A. G., Espie, C. A., Startup, H., Sheaves, B., et al. (2016). Treating sleep problems in patients with schizophrenia. Behavioural and Cognitive Psychotherapy, 44, 273–287.PubMedCrossRef
Walsh, P., Spelman, L., Sharifi, N., & Thakore, J. H. (2005). Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology, 30, 431–437.PubMedCrossRef
Wamsley, E. J., Shinn, A. K., Tucker, M. A., Ono, K. E., McKinley, S. K., Ely, A. V., et al. (2013). The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: A randomized placebo-controlled trial. Sleep, 36, 1369–1376.PubMedPubMedCentralCrossRef
Waters, F., Chiu, V. W., Janca, A., Atkinson, A., & Ree, M. (2015). Preferences for different insomnia treatment options in people with schizophrenia and related psychoses: A qualitative study. Frontiers in Psychology, 6, 990.PubMedPubMedCentralCrossRef
Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998). Natural course of schizophrenic disorders: A 15-Year Followup of a Dutch incidence cohort. Schizophrenia Bulletin, 24(1), 75–85.PubMedCrossRef
Winkelman, J. W. (2001). Schizophrenia, obesity, and obstructive sleep apnea. Journal of Clinical Psychiatry, 62(1), 8–11.CrossRef
Wirshing, D. A., Pierre, J. M., & Wirshing, W. C. (2002). Sleep apnea associated with antipsychotic-induced obesity. Journal of Clinical Psychiatry, 63, 369–670.CrossRef
Włodarczyk, A., Szarmach, J., Cubala, W. J., & Wiglusz, M. S. (2017). Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. Psychiatria Danubina, 29(3), 345–348.PubMed
Yamashita, H., Mori, K., Nagao, M., Okamoto, Y., Morinobu, S., & Yamawaki, S. (2004). Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. Journal of Clinical Psychiatry, 65, 1525–1530.CrossRef
Yates, N. J. (2016). Schizophrenia: The role of sleep and circadian rhythms in regulating dopamine and psychosis. Reviews in the Neurosciences, 27(7), 669–687.PubMedCrossRef
Yujnovsky, I., Hirayama, J., Doi, M., Borrelli, E., & Sassone-Corsi, P. (2006). Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proceedings of the National Academy of Sciences of the United States of America, 103, 6386–6391.PubMedPubMedCentralCrossRef
Yung, A. R., Mcgorry, P. D., Mcfarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (1996). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22, 283–303.PubMedCrossRef
Metagegevens
Titel
Schizofreniespectrum- en andere psychotische stoornissen
Auteurs
Arjen Peters
Drs. Liesanne Brakema
Drs. Marguerite van de Hoeve
Dr. Kor Spoelstra
Dr. Henderikus Knegtering
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
Boek
Slaapstoornissen in de psychiatrie

Print ISBN: 978-90-368-2523-8

Elektronisch ISBN: 978-90-368-2524-5

Copyright: 2021

DOI
https://doi.org/10.1007/978-90-368-2524-5_10